CeriBell (NASDAQ:CBLL) Stock Price Up 9.1% – Here’s Why

Shares of CeriBell (NASDAQ:CBLL) traded up 9.1% during mid-day trading on Tuesday . The company traded as high as $22.91 and last traded at $22.95. 113,825 shares changed hands during mid-day trading, a decline of 46% from the average session volume of 210,938 shares. The stock had previously closed at $21.04.

Analyst Ratings Changes

CBLL has been the topic of several research analyst reports. Canaccord Genuity Group assumed coverage on CeriBell in a research note on Tuesday, November 5th. They set a “buy” rating and a $30.00 price target on the stock. JPMorgan Chase & Co. started coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price target on the stock. William Blair started coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued an “outperform” rating on the stock. TD Cowen upped their price target on shares of CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a report on Monday, December 9th. Finally, Canaccord Genuity Group lifted their price target on CeriBell from $31.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, CeriBell has an average rating of “Buy” and a consensus target price of $32.60.

CeriBell Stock Up 9.0 %

The firm’s 50-day moving average price is $26.14.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($1.03). The business had revenue of $17.20 million for the quarter, compared to the consensus estimate of $17.06 million. As a group, research analysts forecast that CeriBell will post -2.46 EPS for the current year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.